In addition to the above two main biomarkers of clinical efficacy and prognosis, many studies have also indicated that the expression of epidermal growth factor receptor, Ki-67, vascular endothelial growth factor, and BRAF may also be good predicting biomarkers for NPC patients (Cheng et al., 2018; Cao et al., 2019; Chen et al., 2020; Li et al., 2021). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.